Japan· JP-2115404A1051
アミノフィリン水和物
A aminophylline product containing アミノフィリン水和物, registered in Japan by 日新製薬（山形）, on the national reimbursement list. The same ATC class is registered in 11 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Aminophylline is registered in 11 of 19 countries.
Countries holding a registration under ATC R03DA05 (aminophylline), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Aminophylline · ATC R03DA05
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Finlandprice
- Franceprice
- Ireland
- Japan
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- アミノフィリン水和物
- Manufacturer
- 日新製薬（山形）
- Country
- Japan (JP)
- ATC code
- R03DA05
- ATC class
- Aminophylline
- Defined daily dose
- 0.6 g, O
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
323 interactions on record for aminophylline.
Graded by severity as the source publishes them — 34 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Aminophylline · interactions on record
323 records
- 34 severe
- 174 moderate
- 38 minor
- 76 info
Most severe, free to view
- MexiletineC01BB02severe
- RiociguatC02KX05severe
- PindololC07AA03severe
- PropranololC07AA05severe
1 more interaction with mechanism and management, from a commercially licensed source.
Sign in to check- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same class
Other records under R03DA05
Aminophylline, as other registers publish it.
- FinlandAminocontEnnogen Healthcare (Europe) Limited
- FinlandAminocontSchering Oy
- FinlandAminocontSchering Oy
- NorwayAminofilina labesfalLabesfal Laboratorios Almiro
- NorwayAminofillina s.a.l.f.S.A.L.F.
- FinlandAminofyllinSchering Oy
- SwitzerlandAminophyllin Amino, Injektions-/InfusionslösungAmino AG, Fabrikation pharmazeutischer und chemischer Produkte
- United StatesAminophyllineHospira, Inc.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e9cfaeaa-e7e5-4c2f-a15e-e90691d5ca52 GET /v1/drugs/e9cfaeaa-e7e5-4c2f-a15e-e90691d5ca52?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "２．５％１０ｍＬ１管",
"marks": "局",
"source": "mhlw",
"remarks": null,
"yj_code": "2115404A1051",
"category": "注射薬",
"price_yen": 104,
"generic_name": "アミノフィリン水和物",
"product_name_jp": null,
"therapeutic_class": "2115",
"transitional_expiry": null
}See everything about aminophylline.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.